Industry Recognition Highlights EvaThera™ as a Next-Generation Pharmacokinetic Engineering Platform for Precision Radiopharmaceutical Therapy WEST CHESTER, Pa.–(BUSINESS WIRE)–Molecular Targeting…

Read more Molecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera™

Largest Reported Clinical Dataset for an Albumin-Binding Radiotherapeutic Supports the Evans Blue Platform as a Foundational Technology for Next-Generation…

Read more Molecular Targeting Technologies Presents First Clinical Validation of the Evans Blue Platform, Demonstrating Up to 15-Day Tumor Retention Using Approximately 12.5% of the Radioactivity Required for Conventional PRRT

FOR IMMEDIATE RELEASE WEST CHESTER, Pa.–(BUSINESS WIRE)–Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted…

Read more MTTI Highlights Clinical Experience in 81 GEP-NETs Patients and Differentiated Profile of Next-Generation PRRT Candidate EBTATE Following Presentation at SNMMI 2026

FOR IMMEDIATE RELEASE West Chester, PA (Business Wire) – May 28, 2026 – Molecular Targeting Technologies, Inc. (MTTI) announced the…

Read more Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026

FOR IMMEDIATE RELEASE WEST CHESTER, Pa. (BUSINESS WIRE) — Molecular Targeting Technologies, Inc. (MTTI) today announced the appointment of…

Read more MTTI Announces Dr. Danielle Meyrick to Lead Medical Team 

FOR IMMEDIATE RELEASE West Chester, PA, September 12, 2024, 6:01 am Eastern Standard Time (Business Wire) –Molecular Targeting Technologies,…

Read more MTTI Reports on Fast-Acting Sprayable Molecule to Visualize Tumors for Real-Time Fluorescence-Guided Cytoreductive Surgery